Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Mono Pharmacare Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

21%

Sell Order Quantity

79%

Bid Price

Qty

24.65

2000

25.00

2000

24.00

2000

0.00

0

0.00

0

Bid Total

6000

Bid Price

Qty

25.65

2000

27.00

2000

27.00

2000

27.00

16000

0.00

0

Bid Total

22000

Option Chain

Analyzes market sentiment, predicts Mono Pharmacare Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Mono Pharmacare - Updates

    2 Jun 2025, 3:06PM Mono Pharmacare Limited has informed the Exchange regarding the previous outcome of application no. 2025/May/116581/28975, stating that a clerical mi
  • Mono Pharmacare - Outcome of Board Meeting

    31 May 2025, 2:27PM Mono Pharmacare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
  • Mono Pharmacare - Board Meeting Intimation

    27 May 2025, 5:24PM MONO PHARMACARE LIMITED has informed the Exchange about Board Meeting to be held on 30-May-2025 to consider and approve the Yearly Audited Financial r
  • Mono Pharmacare - Board Meeting Intimation

    12 May 2025, 4:26PM MONO PHARMACARE LIMITED has informed the Exchange about Board Meeting to be held on 28-May-2025 to inter-alia consider and approve the Audited Financi
  • Mono Pharmacare has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    20 Apr 2025, 9:10AM As of March 2025, 56.72% is owned by Indian Promoters and 43.28% by Public. <p align=justify> Top two Promoters holding highest number of shares of Mo
  • Mono Pharmacare - Structural Digital Database

    19 Apr 2025, 5:03PM SDD COMPLIENCE CERTIFICATE ISSUED BY MONO PHARMACARE LIMITED FOR THE QUARTER ENDED ON 31.03.2025
  • Mono Pharmacare - Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter

    19 Apr 2025, 1:46PM Mono Pharmacare Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q_ FY 20__-__
  • Mono Pharmacare - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    15 Apr 2025, 12:10PM Mono Pharmacare Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Mono Pharmacare - Board Meeting Intimation

    10 Apr 2025, 7:13PM MONO PHARMACARE LIMITED has informed the Exchange about Board Meeting to be held on 11-Apr-2025 to consider Other business.
  • Mono Pharmacare - Updates

    10 Apr 2025, 7:11PM Mono Pharmacare Limited has informed the Exchange regarding 'cancellation of board meeting due to unforeseen circumstances'.
  • Mono Pharmacare - Board Meeting Intimation

    4 Apr 2025, 7:51PM MONO PHARMACARE LIMITED has informed the Exchange about Board Meeting to be held on 11-Apr-2025 to consider Other business.

Key fundamentals

Evaluate the intrinsic value of Mono Pharmacare Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 54.892 41.3789 25.9045 10.715 9.7761
Liabilities 54.892 41.3789 25.9045 10.715 9.7761
Equity 17.6686 17.6686 12.3686 4.2757 3.6958
Gross Profit 2.5638 2.4518 0.8689 1.2816 0.8469
Net Profit 3.0902 2.4424 0.5418 0.3509 0.0951
Cash From Operating Activities 1.2934 -10.3164 -13.4917 0.2397 -0.7836
NPM(%) 3.73 3.45 3.89 0.94 0.33
Revenue 82.6408 70.7199 13.9161 36.983 28.2661
Expenses 80.077 68.2681 13.0472 35.7014 27.4192
ROE(%) 10.17 8.04 1.78 1.15 0.31

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Mono Pharmacare Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 879.95 5.24 29.20 0.00 301.39 0.57
Lotus Eye Hospital and Institute Ltd 70.78 -0.53 202.23 0.00 3.55 0.00
Vaishali Pharma Ltd 11.54 -0.52 192.33 0.00 3.13 0.00
Astec Lifesciences Ltd 941.80 1.85 0.00 0.00 -687.10 0.00

Company Info

The company was originally formed as a partnership firm in the name and style of "M/s. Mono Chemist" through partnership deed dated May 06, 1994. Promoters of the company Panilam Lakhatariya and Supal Lakhatariya joined the partnership firm on May 10, 2018, as partners of the firm. Further, the Promoters acquired 100% ownership of the partnership firm on July 25, 2019. Further, new partners i.e. Shivlal Gandalal Lakhatariya, Shardaben Shivlal Lakhatariya, Shivam Parag Chauhan, Archit Suhasbhai Shah and Pallaviben Suhasbhai Shah were added pursuant to deed of admission dated June 18, 2022. The partnership firm was then converted into Public Limited company under part I (Chapter XXI) of the Companies Act, 2013 in the name and style of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad. The corporate identification number of the Company is U24304GJ2022PLC136193.Key Events and Milestones:1994- Incorporated Partnership firm in style of `M/s Mono Chemist'2018- Panilam and Supal Lakhatariya are introduced as Incoming partners of Partnership firm.2019- Revenue experienced a growth of more than 2x times after the introduction of the promoters.2022- Conversion of the company from Partnership Firm to Public Limited Company.- Takeover of the business of DLS Export (Proprietorship firm of Panilam Lakhatariya)2023- Takeover of the business of Ahmedabad Medical Corporation and Supal Distributors LLP.

The company was originally formed as a partnership firm in the name and style of "M/s. Mono Chemist" through partnership deed dated May 06, 1994. Promoters of the company Panilam Lakhatariya and Supal Lakhatariya joined the partnership firm on May 10, 2018, as partners of the firm. Further, the Promoters acquired 100% ownership of the partnership firm on July 25, 2019. Further, new partners i.e. Shivlal Gandalal Lakhatariya, Shardaben Shivlal Lakhatariya, Shivam Parag Chauhan, Archit Suhasbhai Shah and Pallaviben Suhasbhai Shah were added pursuant to deed of admission dated June 18, 2022. The partnership firm was then converted into Public Limited company under part I (Chapter XXI) of the Companies Act, 2013 in the name and style of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad. The corporate identification number of the Company is U24304GJ2022PLC136193.Key Events and Milestones:1994- Incorporated Partnership firm in style of `M/s Mono Chemist'2018- Panilam and Supal Lakhatariya are introduced as Incoming partners of Partnership firm.2019- Revenue experienced a growth of more than 2x times after the introduction of the promoters.2022- Conversion of the company from Partnership Firm to Public Limited Company.- Takeover of the business of DLS Export (Proprietorship firm of Panilam Lakhatariya)2023- Takeover of the business of Ahmedabad Medical Corporation and Supal Distributors LLP.

Read More

Parent Organisation

Mono Pharmacare Ltd.

Founded

06/05/1994

Managing Director

Mr.Panilam Lakhatariya

NSE Symbol

MONOPHARMASM

FAQ

The current price of Mono Pharmacare Ltd is

The 52-week high for Mono Pharmacare Ltd is

The market capitalization of Mono Pharmacare Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Mono Pharmacare Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Mono Pharmacare Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Mono Pharmacare Ltd shares.

The CEO of Mono Pharmacare Ltd is Mr.Panilam Lakhatariya, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT